RxDoctor Payments Data

Jolena Martin, PA

Physician Assistant · Saratoga, WYNPI 1184733743

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $792 of the $892 with a category attached, or 88.8%. It is spread thinly across 15 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $617 and has fallen 87.5% since, to $77 in 2024.

$892in general payments, 2019–2025

Across 49 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$141
  • AstraZeneca$128
  • AbbVie$115
  • Lilly USA, LLC$92
  • GSK$88
  • Viiv Healthcare Company$88
  • plus $239 from 9 others

What the payments were for

  • Food & beverage$79289%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$892 in reported general payments places this provider in the 75th percentile of 203 physician assistant providers in Wyoming.

See all physician assistant providers in Wyoming

Medicare billing

Part B allowed, 2024
$50,614
Medicare patients
250
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$25,928
JardianceEmpagliflozin12$13,372
OzempicSemaglutide12$11,245
EliquisApixaban14$10,020
Spiriva RespimatTiotropium Bromide14$6,787
AvaproIrbesartan14$4,809
Pregabalin17$4,623
Levothyroxine Sodium170$3,371
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,275
SynthroidLevothyroxine Sodium39$1,679
Metoprolol Succinate81$1,461
Omeprazole72$1,151
Atorvastatin Calcium94$1,141
Lubiprostone15$1,009
Oxycodone Hcl47$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$92$25,92826 claims
Novo NordiskOzempic$23$11,24512 claims
Sanofi-aventis U.S. LLCAvapro$24$4,80914 claims
AbbVieSynthroid$115$1,67939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 203 physician assistant providers in Wyoming.

Other physician assistant in Saratoga

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →